KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Common Equity (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Common Equity for 7 consecutive years, with $9.7 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 6.07% to $9.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 billion through Dec 2025, down 6.07% year-over-year, with the annual reading at $9.7 billion for FY2025, 6.07% down from the prior year.
  • Common Equity hit $9.7 billion in Q4 2025 for Royalty Pharma, up from $9.6 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $10.4 billion in Q3 2022 to a low of $9.5 billion in Q2 2025.
  • Historically, Common Equity has averaged $10.0 billion across 5 years, with a median of $9.9 billion in 2021.
  • Biggest five-year swings in Common Equity: surged 37.34% in 2021 and later decreased 7.98% in 2023.
  • Year by year, Common Equity stood at $10.2 billion in 2021, then decreased by 7.06% to $9.5 billion in 2022, then rose by 5.87% to $10.1 billion in 2023, then rose by 2.56% to $10.3 billion in 2024, then fell by 6.07% to $9.7 billion in 2025.
  • Business Quant data shows Common Equity for RPRX at $9.7 billion in Q4 2025, $9.6 billion in Q3 2025, and $9.5 billion in Q2 2025.